Saroglitazar: all 21 studies that test it
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyRecruitingNCT07424677Phase 3
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesRecruitingNCT07216235Phase 3
- Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver DiseaseRecruitingNCT06825559Phase 1
- A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With ComorbiditiesRecruitingNCT05872269Phase 4
- Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseaseRecruitingNCT05045482Phase 1
- Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USTerminatedNCT05211284Phase 2Results posted
- Saroglitazar Magnesium in the Treatment of Non-Alcoholic SteatohepatitisCompletedNCT03863574Phase 2Results posted
- Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03639623Phase 2Results posted
- Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)TerminatedNCT03617263Phase 2Results posted
- Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary CholangitisCompletedNCT03112681Phase 2Results posted
- Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisCompletedNCT03061721Phase 2Results posted
- Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary CholangitisActive, not recruitingNCT06427395Phase 3
- Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisCompletedNCT05133336Phase 2/3
- Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisCompletedNCT05011305Phase 2
- Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic FunctionCompletedNCT04469920Phase 1
- A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal FunctionCompletedNCT04446507Phase 1
- An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)Status unknownNCT04193982Phase 3
- Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male SubjectsCompletedNCT04112446Phase 1
- A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy VolunteersCompletedNCT04045769Phase 1
- Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dLSuspendedNCT03097107Phase 2
- A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr DiseaseStatus unknownNCT02265276Phase 3